evipedia.aidev
← Back

Monolaurin for Health & Longevity

Evidence Review created on 08/26/2026 using AI4L / Grok 4.5

Also known as: Glycerol Monolaurate, Glyceryl Laurate, GML, 1-Monolaurin, 1-Lauroyl-glycerol, Lauricidin

Motivation

Monolaurin is a fat-like compound formed when glycerol joins lauric acid, a twelve-carbon fatty acid present in coconut oil, palm kernel oil, and human milk. The body can make small amounts from dietary lauric acid, but conversion is inefficient, so concentrated capsules and pellets are sold as supplements. Interest among health-optimizing adults comes from laboratory work showing that the molecule can disrupt the fatty coats of certain microbes.

Researchers in the 1970s found this particular form unusually active against selected bacteria compared with other fatty acids, and food regulators later listed related fats as ordinary mixing agents in packaged foods. Human studies of swallowed monolaurin as a supplement remain sparse. The better-controlled trials use vaginal gels or tampon fibers rather than oral doses, and mouse work on weight and inflammation has pointed in opposite directions depending on diet.

This review examines the evidence that oral or topical monolaurin changes infection burden, immune signaling, and metabolic health in adults who already treat sleep, food, and training as a base, and it sets those claims next to the available safety data.

Benefits - Risks - Protocol - Conclusion

High-level overviews and primary papers that name monolaurin and map the gap between laboratory killing assays and human use.

Dedicated overviews from Peter Attia, Andrew Huberman, Life Extension Magazine, and Lifespan.io were not found. Rhonda Patrick’s FoundMyFitness library names monolaurin only in passing as a breast-milk lipid, without a standalone overview. Kresser Institute knowledge-base Q&A pages that discuss monolaurin are excluded as Q&A.

Grokipedia

  • Monolaurin

    Chemistry, occurrence, antimicrobial mechanisms, food-additive use, and the thin human clinical file, including the point that oral supplement trials are largely absent.

Examine

No Examine.com article for monolaurin was found.

ConsumerLab

No ConsumerLab article for monolaurin was found.

Systematic Reviews

No systematic reviews or meta-analyses for Monolaurin were found on PubMed as of August 26, 2026.

Mechanism of Action

Monolaurin (glycerol monolaurate, GML) is the monoester of glycerol and lauric acid. The amphiphilic molecule inserts into lipid bilayers. In microbes this solubilizes envelope phospholipids, collapsing membranes of many gram-positive bacteria, Candida yeasts, and enveloped viruses at concentrations about 200-fold lower than free lauric acid. Gram-negative rods such as Pseudomonas are relatively spared unless the outer membrane is opened. The same surfactant action disrupts biofilms and can block staphylococcal superantigen production below killing concentrations.

In human T cells (adaptive white cells) and B cells (antibody-producing cells), GML alters plasma-membrane order, impairs microcluster formation of LAT (a T-cell adapter protein) and related proteins, and cuts PI3K–AKT signaling (phosphoinositide 3-kinase–protein kinase B, a growth and survival cascade) and calcium flux, lowering interleukin-2, interferon-gamma, tumor necrosis factor-alpha, and interleukin-10. That immune-dampening action is proposed as useful against toxin-driven inflammation and as a theoretical risk for host defense.

Orally, pancreatic lipase and monoacylglycerol lipase (MAG lipase, the enzyme that splits monoglycerides) hydrolyze GML to glycerol and lauric acid; residual intact monoglyceride can enter lymph. Human half-life, tissue distribution, and cytochrome P450 (CYP, liver drug-metabolizing enzymes) involvement are not defined; metabolism is lipase-driven rather than CYP-dependent. Selectivity is physicochemical (twelve-carbon chain, monoester) rather than receptor-based.

Historical Context & Evolution

Jon J. Kabara’s 1972 screen of fatty acids and esters identified lauric acid and its monoglyceride as among the most bactericidal lipids against gram-positive organisms. Kabara later commercialized a distilled pellet (Lauricidin), so later dosing lore is tied to that product line. Food and cosmetic law treated glyceryl laurate as an emulsifier: the U.S. Food and Drug Administration (FDA) lists related mono- and diglycerides as generally recognized as safe, and a 2004 cosmetics-industry-funded Cosmetic Ingredient Review (Personal Care Products Council) concluded glyceryl laurate was safe in then-current cosmetic use after hydrolysis to glycerol and lauric acid.

Patrick Schlievert’s group (with patents on GML formulations) moved the compound into tampon finishes and vaginal gels to blunt toxic-shock toxin and vaginal pathogens. A 2009 Nature macaque study reported that vaginal GML blocked simian immunodeficiency virus transmission by damping mucosal inflammatory recruitment of target cells. A 2019 chiropractic narrative review found no peer-reviewed oral-supplement antimicrobial trial. Mouse feeding studies from a Zhejiang University food-science group then split: low-dose GML on a low-fat diet induced metabolic syndrome in 2018, while higher doses on high-fat diets later improved weight and lipids. A 2020 multicenter vaginal-gel trial did not beat vehicle for bacterial vaginosis. The oral longevity file remains an extrapolation from these topical and rodent lines, not a closed human question.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human outcomes are from single topical trials, and oral antimicrobial findings are in-vitro minimum-inhibitory-concentration (MIC, the lowest culture concentration that stops growth) assays.

Medium 🟩 🟩

No benefit reaches Medium: the human findings are single-trial local microbiology or toxin and cytokine shifts, not a validated clinical endpoint or consistent observational clinical outcome.

Low 🟩

Reduction of Vaginal Candida and Gardnerella Counts

A randomized, double-blind gel study had women use 0%, 0.5%, or 5% GML twice daily for two days. GML gels lowered Candida and Gardnerella vaginalis counts without reducing Lactobacillus or changing vaginal pH. A later multicenter trial found 5% gel no better than vehicle for clinical bacterial-vaginosis cure.

Magnitude: Direction holds for 0.5–5% vaginal gel over two days; the literature reports no standardized effect-size figure for colony counts and no oral equivalent. (Strandberg et al., 2010; Mancuso et al., 2020)

Lower Staphylococcal Exotoxin During Tampon Use

On menstrual day 2, 225 women wore a blinded tampon with or without GML for 4–6 hours. Among 41 women (18%) with recoverable Staphylococcus aureus, GML tampons carried less toxic shock syndrome toxin 1 (TSST-1, a superantigen) and alpha-toxin, and vaginal interleukin-8 was lower.

Magnitude: Among S. aureus-colonized wearers, exotoxin and interleukin-8 were lower with GML than without; the paper does not report a single pooled percentage reduction suitable as a universal effect size. (Strandberg et al., 2009)

Higher Circulating Monolaurin and Lower COVID-19 Incidence

In 1,000 hospital workers, higher baseline serum monolaurin associated with fewer COVID-19 cases over six months, with a 0.45 µg/mL cut-off. The study measured circulating lipid, not a capsule. Diet and coconut intake were not isolated.

Magnitude: Odds of infection were 2.56-fold higher at 3 months and 3.34-fold higher at 6 months below 0.45 µg/mL serum monolaurin; Cox models (a time-to-event analysis that estimates relative risk over follow-up) estimated about 67% lower relative risk above that cut-off in one observational cohort, not a supplementation trial. (Sola et al., 2025)

Lower Oral Helicobacter pylori Antigen with Glycerol-Monolaurate Mouthwash

A trial of a lysine plus 0.2% glycerol monolaurate mouthwash reported higher clearance of oral Helicobacter pylori (H. pylori, a stomach bacterium) antigen than gastric drugs or teeth cleaning, and higher later gastric-eradication success. The rinse is a combination product, not a swallowed capsule.

Magnitude: Oral antigen clearance about 73% with the mouthwash versus under 11% with standard gastric drugs or cleaning in that trial; not an oral-supplement result. (Wang et al., 2014)

Speculative 🟨

Broad-Spectrum Killing of Enveloped Viruses and Gram-Positive Bacteria

In-vitro assays show envelope rupture of selected microbes at low concentrations. Basis is laboratory culture work only. (Hierholzer & Kabara, 1982)

Metabolic and Gut-Microbiota Shifts ⚠️ Conflicted

Low-dose GML raised mouse weight on a low-fat diet; high-fat studies found the reverse. Net reading: diet-specific rodent effects; humans untested. (Jiang et al., 2018)

Biofilm Disruption

GML prevents S. aureus biofilm formation and kills cells inside mature biofilms in vitro, without resistance after a year of sublethal passage. Human biofilm disease outcomes are untested. (Schlievert & Peterson, 2012)

Benefit-Modifying Factors

  • Genetic polymorphisms: No clinical pharmacogenetic map exists. Variants in pancreatic lipase or MAG lipase could theoretically change how much intact GML survives digestion; this has not been tested in people.

  • Baseline biomarkers: No validated responder marker. One cohort used serum monolaurin 0.45 µg/mL as an epidemiologic cut-off, not a dosing target for capsules.

  • Sex: Oral data are not sex-stratified. Vaginal-gel and tampon trials enrolled only women, so those microbiology signals do not automatically transfer to men.

  • Pre-existing conditions: Mouse colitis models improved on oral GML; human inflammatory bowel disease data are absent. Skin and vaginal staphylococcal or yeast burden is the setting of the topical human work.

  • Age: No age-stratified oral trials. A pediatric ointment study exists for skin infection; older adults have no dedicated oral safety series.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: documented human adverse events come from a single vaginal-gel trial, and oral supplement series have not mapped dose-related harm.

Medium 🟥 🟥

Local Urogenital Irritation with Vaginal Gel

In the 109-person bacterial vaginosis gel trial, about two-thirds of both GML and vehicle users reported solicited urogenital symptoms (burning, itch, pain), mostly mild to moderate; product-related serious events were zero. The signal tracks the glycol vehicle as much as GML.

Magnitude: Solicited urogenital events in about two-thirds of both GML (n=73) and vehicle (n=36) users (not statistically different); no product-related serious events. (Mancuso et al., 2020)

Low 🟥

Skin Irritation at High Topical Concentrations

A cosmetics-industry-funded Cosmetic Ingredient Review of glyceryl laurate found little systemic toxicity after hydrolysis to glycerol and lauric acid. Undiluted material can mildly irritate skin; above-cosmetic concentrations caused moderate redness on human repeat-insult patch testing. Standard leave-on cosmetic levels were not sensitizing.

Magnitude: Irritation appears at undiluted or above-cosmetic topical concentrations; cosmetic-use levels up to the reviewed 12% class maximum were generally non-sensitizing. (CIR, 2004)

Speculative 🟨

Suppression of T-Cell and B-Cell Signaling

GML cuts cytokine output in cultured T cells and B cells. Basis is in-vitro signaling only. (Zhang et al., 2016)

Metabolic Syndrome and Dysbiosis at Low Dietary Doses ⚠️ Conflicted

Low-dose GML raised mouse weight on a low-fat diet; later high-fat studies found the reverse. Net reading: diet-specific rodent harm, not a shown human event. (Jiang et al., 2018)

Transient Flu-Like Symptoms on Rapid Dose Escalation

Integrative clinicians describe flu-like symptoms when oral doses rise quickly. No controlled series quantifies this. The basis is anecdote plus in-vitro microbial killing.

Gastrointestinal Intolerance with Oral Doses

Users and practitioner sources describe nausea, loose stool, or fat-load discomfort when oral doses rise quickly. No controlled oral series quantifies this. The basis is anecdote plus rapid lipase hydrolysis of a lipid load.

Risk-Modifying Factors

  • Genetic polymorphisms: None established. Lipase-pathway variants could change intact GML exposure; this remains theoretical.

  • Baseline biomarkers: Higher starting inflammatory tone or lipopolysaccharide load is the rodent setting in which low-dose GML looked worse; no human threshold exists.

  • Sex: Vaginal burning and itch data are from women using gel. Oral sex differences in adverse events have not been reported because oral trials are missing.

  • Pre-existing conditions: Known allergy to glyceryl laurate is a hard stop. Theoretical caution applies in clinically important immunosuppression given in-vitro T-cell and B-cell suppression.

  • Age: Older adults have no dedicated oral series; cosmetic and food-additive experience is not a high-dose supplement safety file.

Key Interactions & Contraindications

  • Prescription antimicrobials: In-vitro synergy with beta-lactams (penicillins, cephalosporins such as amoxicillin) against S. aureus is reported. Severity: monitor. Consequence: unpredictable additive killing, not a proven clinical benefit. (Ghany et al., 2024)

  • Immunosuppressants (tacrolimus, cyclosporine, systemic corticosteroids): Theoretical additive damping of T-cell signaling. Severity: caution. Consequence: unmeasured extra immune suppression. Separate new oral GML from dose changes and watch infection rate.

  • Over-the-counter antifungals and antibacterials (miconazole, bacitracin): Possible local additive irritation if stacked with topical GML. Severity: caution. Consequence: more burning or dermatitis. Avoid combining on broken skin without a washout.

  • Probiotics and other antimicrobials (berberine, oregano oil): Overlapping gut-microbe pressure. Severity: monitor. Consequence: excess flu-like symptoms from microbial killing or microbiota swing. Stagger start dates and titrate one agent at a time.

  • Coconut oil and medium-chain triglyceride oils: Additive lauric-acid load, not equivalent GML dose. Severity: monitor. Consequence: more gastrointestinal fat load without predictable extra antimicrobial effect.

  • Fat-soluble oral medications: Intact monoglyceride could theoretically alter mixed-micelle absorption. Severity: caution. Consequence: unknown change in drug exposure. Separate by several hours when feasible.

Populations who should avoid Monolaurin:

  • Individuals with known allergy to glyceryl laurate, glycerol monolaurate, or monolaurin
  • Pregnancy, until reproductive toxicology for supplemental doses is available (fetal effects are unknown)
  • Clinically important immunosuppression when the goal is to preserve residual adaptive immunity (theoretical, in-vitro T-cell and B-cell suppression)

Risk Mitigation Strategies

  • Slow oral titration: Start at about 0.75 g once or twice daily and increase every several days. Mitigates transient flu-like symptoms from microbial killing and unmasking of gastrointestinal intolerance.

  • Split doses: Divide the daily amount into two or three portions. Mitigates peak local gut load from a lipid that is rapidly hydrolyzed rather than stored as a long half-life drug.

  • Topical concentration cap: Keep leave-on skin products in the cosmetic-use range rather than undiluted GML. Mitigates irritant dermatitis seen at high topical concentrations.

  • Infection surveillance on high dose: Track fever, new infections, and white-cell trends if doses approach several grams daily. Mitigates theoretical adaptive-immune damping.

  • Metabolic check on long-term use: Repeat fasting lipids and waist circumference after 8–12 weeks. Mitigates the unresolved rodent signal of diet-dependent metabolic shift.

Therapeutic Protocol

  • Kabara / Lauricidin pellet titration: The originating investigator’s commercial line uses small pellets so sensitive users can start at a few pellets and build toward about 3 g two to three times daily. Kabara commercialized the product.

  • Capsule gram-dosing: Generic 600–1,000 mg capsules are often started at one capsule twice daily with food, then increased. This is less granular than pellets and is not backed by an oral randomized controlled trial (RCT).

  • Topical-only path: Vaginal gels (0.5–5%) and tampon finishes were the designs used in controlled human work; they are a different exposure from swallowed pellets.

  • Time of day: Split morning and evening with meals. There is no circadian efficacy dataset; meals aid swallowing of a waxy lipid.

  • Half-life and splitting: Human oral half-life is not measured. Lipase hydrolysis is expected within hours, which is why practitioners split the daily amount rather than using a single bolus.

  • Genetic polymorphisms: No protocol change is established for MAG lipase or other variants; empiric titration remains the method.

  • Sex: No sex-specific oral dose. Vaginal protocols apply only to people with a vagina.

  • Age: Older adults use the same slow titration in the absence of geriatric half-life data; pediatric ointment work does not set an adult oral dose.

  • Baseline biomarkers: No lab gate. Practitioners who use high doses often want a recent lipid panel and infection history on file first.

  • Pre-existing conditions: Active severe immunodeficiency is a reason some clinicians avoid high oral doses; mild mucosal yeast or staphylococcal colonization is the usual integrative use-case.

Discontinuation & Cycling

  • Duration of use: Not a demonstrated lifelong longevity drug. Integrative use is often seasonal or during suspected viral or yeast flares; food-additive exposure is lifelong at much lower doses.

  • Withdrawal: No withdrawal syndrome is described. Stopping does not require a pharmacologic taper for receptor rebound.

  • Taper: A short step-down over several days is used only to separate those flu-like symptoms from other causes, not because of dependence.

  • Cycling: No evidence that cycling preserves efficacy. In-vitro S. aureus did not acquire GML resistance after a year of sublethal passage.

  • Restart: After a break, restarting at a mid-range rather than peak dose is the usual caution for gastrointestinal comfort.

Sourcing and Quality

  • Identity: Labels that name glycerol monolaurate or glyceryl laurate, rather than only “coconut oil” or “lauric acid,” identify the actual ester; those oils are not dose-equivalent.

  • Third-party testing: Prefer lots with identity and purity certificates (USP, NSF, or equivalent). The FDA does not pre-approve supplement content.

  • Form: Distilled pellets (Lauricidin) allow milligram-scale starts; capsules are more convenient but coarser. Alpha-mono content is the antimicrobial-relevant isomer in food-grade GML.

  • Reputable makers: Lauricidin is the historically cited pellet. Designs for Health and other professional lines sell capsules; they also market the ingredient, which is a commercial conflict.

  • Cosmetic versus supplement: Glyceryl laurate in lotions is a different dose and route from gram-level oral pellets and should not be treated as the same intervention.

Practical Considerations

  • Time to effect: Topical microbiology shifts were measured in hours to two days. Oral users who report fewer winter infections are describing uncontrolled timelines, not a trial-defined onset.

  • Common pitfalls: Equating tablespoons of coconut oil with a capsule dose; jumping to several grams and attributing malaise to microbial killing; expecting vaginal-gel results from swallowed pellets.

  • Regulatory status: Sold under the Dietary Supplement Health and Education Act (DSHEA) in the United States. Mono- and diglycerides are generally recognized as safe food additives (21 CFR 184.1505). The FDA has not approved monolaurin to treat infection.

  • Cost and access: Capsules and pellets are inexpensive over-the-counter items, not a high-barrier compounding drug.

  • Label claims: Immune and yeast-balance language is structure/function wording, not an infection-treatment indication.

Interaction with Foundational Habits

  • Sleep: Direct: none demonstrated. Indirect: if nocturnal gastrointestinal discomfort occurs with large evening fat loads, moving the last dose earlier can protect sleep continuity.

  • Nutrition: Direct: GML is a digestible monoglyceride; taking it with meals eases swallowing. Coconut oil is not a substitute. High background saturated-fat intake is the rodent setting in which high-dose GML looked metabolically better, which is not a dietary prescription.

  • Exercise: None demonstrated. No evidence that GML blunts hypertrophy or endurance. Timing around workouts is unstudied; avoid new high doses on key training days only to keep gastrointestinal variables stable.

  • Stress management: Indirect: in-vitro cytokine suppression is not a cortisol or stress-practice substitute. No named human trial links GML to perceived stress or heart-rate variability.

Monitoring Protocol & Defining Success

Before a first high-dose oral trial, a baseline set of ordinary metabolic and inflammatory labs documents the starting point, because rodent data leave open a diet-dependent lipid and inflammation shift and because in-vitro lymphocyte work has no human immune-function counterpart. Ongoing checks are sparse: repeat the same panel after the first 8–12 weeks, then every 6–12 months if use continues, rather than a drug-style weekly schedule. There is no validated “monolaurin level” for capsules; the 0.45 µg/mL serum figure from the COVID-19 cohort is epidemiologic, not a therapeutic range. Qualitative tracking of bowel tolerance, new infections, and skin or mucosal symptoms carries as much weight as the table below, given the absence of an oral efficacy biomarker.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP <1.0 mg/L (often <0.5 mg/L in prevention practice) Flags a systemic inflammatory shift High-sensitivity C-reactive protein. Conventional labs often call <3.0 mg/L acceptable; functional targets are tighter. Non-fasting OK.
Fasting triglycerides <100 mg/dL functional; <150 mg/dL conventional Mouse low-dose GML raised triglycerides 8–12 hour fast. Pair with high-density lipoprotein (HDL).
LDL cholesterol Context-dependent; many prevention clinics aim <100 mg/dL Rodent lipid shifts were diet-specific Low-density lipoprotein (LDL). Conventional “normal” can reach ~129 mg/dL. Fasting preferred if also measuring triglycerides.
Fasting glucose 70–90 mg/dL functional vs <100 mg/dL conventional Mouse glycemic markers were followed in feeding studies Morning fast. Pair with glycated hemoglobin (HbA1c, a three-month glucose average) if use is chronic.
Waist circumference Track change from personal baseline; no GML-specific target Mouse visceral-fat findings were directionally mixed Same tape method each visit; not a lab.

Qualitative markers:

  • Gastrointestinal comfort after dose increases (cramping, loose stool)
  • Frequency of winter respiratory or mucosal yeast flares relative to the person’s own baseline
  • New or unusual infections if doses stay in the multi-gram range
  • Local burning or dermatitis if a topical product is added

Emerging Research

  • Radiation-dermatitis hydrogel (recruiting): Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis (NCT05079763) is a 54-person pilot RCT in the Philippines. A positive result would support topical barrier use; a null result would further confine human benefit to narrow mucosal settings.

  • Pediatric skin ointment (completed, unpublished results): Monolaurin Ointment Versus Mupirocin Ointment (NCT06046937), n=40, early phase 1, tested community skin infection. Posted results could strengthen or weaken topical antibacterial claims versus a standard antibiotic.

  • Vaginal gel already negative for clinical cure: The completed 5% Monolaurin Vaginal Gel trial (NCT02709005; Mancuso et al., 2020) found no advantage over vehicle for bacterial vaginosis. That result already weakens “broad human antimicrobial” marketing for this route.

  • Endogenous monolaurin and COVID-19: Sola et al., 2025 associated higher serum monolaurin with fewer infections. A randomized oral-supplementation trial could support or refute a causal, doseable effect.

  • Rodent metabolic split: Jiang et al., 2018 versus Zhao et al., 2020 still needs a human feeding study. Either direction would move oral GML toward, or away from, metabolic-health use.

  • Adaptive-immune suppression: Zhang et al., 2016 and Fosdick et al., 2022 show T-cell and B-cell inhibition in culture. An ex-vivo study after oral dosing could confirm or dismiss this as a clinical risk.

Conclusion

Monolaurin is a coconut- and milk-derived fat-like compound sold as a concentrated oral supplement and used in foods and cosmetics as a mixing agent. Laboratory work shows that it can break the outer coating of selected bacteria, yeasts, and fatty-coated viruses at doses far below free lauric acid. That laboratory signal is why longevity-oriented users consider it for immune and gut microbial balance.

In people, the only randomized evidence is topical: vaginal gel reduced some yeast and vaginal-bacteria counts in a small study but did not cure bacterial vaginosis in a larger trial, and tampon fibers lowered staphylococcal toxin during menstrual use. No peer-reviewed trial has tested swallowed monolaurin against infection, inflammation, or aging outcomes. One observational cohort linked higher blood monolaurin — not a supplement — with fewer COVID-19 cases. Mouse studies of diet-level doses point in opposite directions on weight and inflammation depending on diet. Several key papers come from investigators with patents or brands (Lauricidin; glycerol monolaurate tampon and gel formulations). Skin and mucosal irritation data rest on a cosmetics-industry-funded ingredient review.

Safety as a food mixing agent is long-standing, and short topical courses produced mostly mild local symptoms similar to placebo gel. Oral supplement series have not mapped dose, blood levels, or immune-cell effects in people. Lab-culture studies show the same molecule can dampen white-cell activation, an uncertainty for chronic high-dose use. For a risk-aware adult already managing sleep, food, and training, the evidence is from laboratory work and skin or mucosal use, not a demonstrated longevity intervention.

Top - Benefits - Risks - Protocol